Earnings
TG Therapeutics Sees Self-Administered BRIUMVI Potentially More Than Doubling Its Peak-Sales Opportunity
Management plans an auto-injector launch in 2028, while raising its U.S. product-sales forecast to $915–920 million.
TG Therapeutics (TGTX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Management plans an auto-injector launch in 2028, while raising its U.S. product-sales forecast to $915–920 million.
Earnings
U.S. BRIUMVI sales grew approximately 52% in the third quarter, with new dosing options moving through clinical trials.